MBX Biosciences is a preclinical-stage biotech company committed to creating therapies to treat rare endocrine diseases where there is inadequate treatment available. MBX’s leadership team has collaborated successfully over several decades to discover, develop, and commercialize first-in-class endocrine therapeutics. A distinguishing strength of MBX is world-class proprietary peptide drug discovery.
MBX’s clinical program for its lead clinical candidate will commence in mid-2021. The company is building a pipeline of additional product candidates targeting rare endocrine disorders that are targeted to enter Phase 1 development by the end of 2021.
MBX recently closed a $34.6 million Series A financing led by Frazier Healthcare Partners, with participation from OrbiMed, New Enterprise Associates, Indiana Philanthropic Venture Fund (IUPhV) Indiana Seed Fund III (managed by BioCrossroads) and Twilight Venture Partners II which will fund MBX’s next stage of development building a world-class drug development company in Indianapolis, Indiana.